Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
30 hedge funds and large institutions have $2.22M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
41% less capital invested
Capital invested by funds: $3.76M → $2.22M (-$1.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$133K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.3K |
| 3 |
Renaissance Technologies
New York
|
+$20.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$1.19K |
| 2 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
-$1K |
| 3 |
Morgan Stanley
New York
|
-$434 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$376 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$76 |
BLCM Hedge Fund Activity: Q2 2022 in Review
30 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2022, worth a combined $2.22M — down 41% from $3.76M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BLCM positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Long Focus Capital Management, adding an estimated $133K. The largest seller was LPL Financial, cutting an estimated $1.19K.
- 30 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2022, up from 29 in Q1 2022.
- Funds reported $2.22M of Bellicum Pharmaceuticals, Inc. stock for Q2 2022, down 41% quarter-over-quarter.
- 4 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2022 and 3 closed out, a net change of +1 holder.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2022 was Long Focus Capital Management, an estimated $133K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2022 was LPL Financial, an estimated $1.19K sold.
Based on aggregated 13F filings for Q2 2022.